or Try an Advanced Search...

    Regeneron Stocks List

    Symbol Grade Name % Change
    SNY F Sanofi -0.42
    REGN F Regeneron Pharmaceuticals, Inc. 0.42
    ADVM F Adverum Biotechnologies, Inc. -2.44
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development

    Related ETFs - A few ETFs which own one or more of the above listed Regeneron stocks.

    Symbol Grade Name Weight
    PINK D Simplify Health Care ETF 9.08
    IBBQ D Invesco Nasdaq Biotechnology ETF 7.18
    BBH D Market Vectors Biotech ETF 6.9
    IBB D iShares Nasdaq Biotechnology Index Fund 5.67
    BIB F ProShares Ultra Nasdaq Biotechnology 5.48
    View all Regeneron ETFs...
    Compare ETFs
    Compare IBBQ to BIB Compare PINK to BBH Compare PINK to IBB

        Regeneron Stocks Recent News

        Date Stock Title
        Nov 20 ADVM Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
        Nov 20 SNY CDC warns of an imminent spike in COVID, flu cases
        Nov 20 SNY Here’s What Drove Sanofi’s (SNY) Earnings
        Nov 20 SNY Sanofi: Information concerning the total number of voting rights and shares - October 2024
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 REGN Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript)
        Nov 19 REGN Regeneron: The Biotech Stock To Buy Now
        Nov 19 REGN Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
        Nov 18 REGN FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
        Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
        Nov 18 ADVM Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
        Nov 18 ADVM Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
        Nov 18 ADVM Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
        Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
        Nov 15 ADVM Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
        Nov 15 REGN FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
        Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
        Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
        Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
        Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development
        Regeneron

        Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

        More about Regeneron
        Browse All Tags